Joshi et al. [16] reported similar findings and concluded that SGLT2 inhibitors are the most advanced and effective therapeutic option for patients with type 2 diabetes mellitus (T2DM) and cardiovascular diseases due to their ability to improve blood glucose control [43]. The gene discussed is SLC5A2; the disease is diabetes mellitus.